aTyr Pharma CFO Jill Broadfoot To Step Down Sept. 30, 2026

aTyr Pharma Announces It Expects FDA Response Regarding Its Submitted Protocol For Phase 3 Trial Of Efzofitimod To Treat Pulmonary Sarcoidosis With Restrictive Lung Disease In Mid-September

aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase

aTyr Pharma Announces Workforce Reduction Of About 60% To Focus On Efzofitimod Program; Expects $13M Reduction In Annualized Operating Expenses Beginning Q4 2026

aTyr Pharma CFO Jill Broadfoot To Step Down As Of September 30; To Be Succeeded By Brandon Yaras As Of October 1

aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase